EA201900293A3 - TRANSDERMAL DRUG FOR TREATMENT AND PREVENTION OF DISEASES OF JOINTS AND SOFT TISSUES - Google Patents
TRANSDERMAL DRUG FOR TREATMENT AND PREVENTION OF DISEASES OF JOINTS AND SOFT TISSUESInfo
- Publication number
- EA201900293A3 EA201900293A3 EA201900293A EA201900293A EA201900293A3 EA 201900293 A3 EA201900293 A3 EA 201900293A3 EA 201900293 A EA201900293 A EA 201900293A EA 201900293 A EA201900293 A EA 201900293A EA 201900293 A3 EA201900293 A3 EA 201900293A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- drug
- composition
- inflammatory
- joints
- diseases
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 5
- 229940079593 drug Drugs 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 210000004872 soft tissue Anatomy 0.000 title abstract 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 abstract 2
- 229960000991 ketoprofen Drugs 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001760 anti-analgesic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 abstract 1
- 235000010262 sodium metabisulphite Nutrition 0.000 abstract 1
- 239000004296 sodium metabisulphite Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001562 ulcerogenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к области медицины и химико-фармацевтической промышленности, а именно к трансдермальным препаратам для профилактики и лечения болезней суставов и мягких тканей, содержащих в качестве активных компонентов хондропротекторы и нестероидные противовоспалительные средства. Предложен новый состав вспомогательных веществ, обеспечивающий повышенную стабильность глюкозамина гидрохлорида и кетопрофена с образованием минимального количества примесей в процессе хранения. Срок годности препарата с предлагаемым составом не менее 2-х лет. Повышение стабильности действующих веществ достигается за счёт использования в составе полиэтиленгликоля 400 и натрия метабисульфита. Кроме того, препарат с новым составом оказывает эффективное противовоспалительное и анальгетическое действие при концентрации кетопрофена меньше на 20% по сравнению с находящимися на рынке препаратами, что позволяет снизить риск возникновения ульцерогенного эффекта от применения этого нестероидного противовоспалительного средства.SUBSTANCE: invention relates to medicine and chemical-pharmaceutical industry, namely to transdermal preparations for the prevention and treatment of diseases of the joints and soft tissues, containing chondroprotectors and non-steroidal anti-inflammatory drugs as active components. A new composition of excipients has been proposed that provides increased stability of glucosamine hydrochloride and ketoprofen with the formation of a minimum amount of impurities during storage. The shelf life of the drug with the proposed composition is at least 2 years. An increase in the stability of active ingredients is achieved through the use of polyethylene glycol 400 and sodium metabisulphite in the composition. In addition, the drug with a new composition has an effective anti-inflammatory and analgesic effect at a concentration of ketoprofen less than 20% compared to drugs on the market, which reduces the risk of an ulcerogenic effect from the use of this non-steroidal anti-inflammatory drug.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018122768A RU2685436C1 (en) | 2018-06-22 | 2018-06-22 | Transdermal preparation for treatment and prevention of diseases of joints and soft tissues |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201900293A2 EA201900293A2 (en) | 2019-12-30 |
| EA201900293A3 true EA201900293A3 (en) | 2020-01-31 |
| EA039612B1 EA039612B1 (en) | 2022-02-16 |
Family
ID=66168206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201900293A EA039612B1 (en) | 2018-06-22 | 2019-06-14 | Transdermal preparation for treatment and prevention of diseases of joints and soft tissues |
Country Status (2)
| Country | Link |
|---|---|
| EA (1) | EA039612B1 (en) |
| RU (1) | RU2685436C1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100416305B1 (en) * | 2000-06-21 | 2004-01-31 | 제일약품주식회사 | Transdermal system consisted of ketoprofen and water-soluble acrylic emulsion adhesive |
| CN1547474A (en) * | 2001-05-31 | 2004-11-17 | Skin-permeable selective cyclooxygenase-2 inhibitor composition | |
| MXPA06011475A (en) * | 2004-04-07 | 2007-04-25 | Univ Georgia Res Found | Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods. |
| AU2006228869A1 (en) * | 2005-03-30 | 2006-10-05 | Astion Pharma A/S | Oxaprozin or a closely related compound for the treatment of eczema |
| CN101518520B (en) * | 2009-04-09 | 2011-07-27 | 浙江省医学科学院 | Framework-type transdermal patch with dextro ketoprofen accumulated in subcutaneous deep tissues |
| RU2582278C2 (en) * | 2013-04-25 | 2016-04-20 | Закрытое Акционерное Общество "Фармфирма "Сотекс" | Transdermal agent for treating and preventing joint and soft tissue diseases, method for production thereof and combined transdermal preparation for treating and preventing joint and soft tissue diseases |
-
2018
- 2018-06-22 RU RU2018122768A patent/RU2685436C1/en active
-
2019
- 2019-06-14 EA EA201900293A patent/EA039612B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA039612B1 (en) | 2022-02-16 |
| RU2685436C1 (en) | 2019-04-18 |
| EA201900293A2 (en) | 2019-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090955A1 (en) | METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS | |
| EA201490163A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
| RU2016135952A (en) | DOPA-DECARBOXYLASE INHIBITOR COMPOSITIONS | |
| EA200870469A1 (en) | NEW, CONTAINING NIMESULIDE, PHARMACEUTICAL COMPOSITIONS WITH LOW DOSE, THEIR RECEPTION AND APPLICATION | |
| BR112012030641A2 (en) | methods and compositions for oral pharmaceutical therapy | |
| EA202192322A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| EA202190115A1 (en) | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS FOR THEIR PREPARATION | |
| US10391074B2 (en) | Topical preparation for pain relief | |
| JP5403935B2 (en) | Oral chronic pain prevention or treatment agent | |
| EA200500941A1 (en) | MEANS FOR TREATING JOINT DISEASES | |
| BR112012020185A2 (en) | use of oral heparin preparations to treat urinary tract diseases and disorders. | |
| EA202190334A1 (en) | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION WITH MODIFIED RELEASE | |
| AR066666A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVING AGENT | |
| EA201900293A3 (en) | TRANSDERMAL DRUG FOR TREATMENT AND PREVENTION OF DISEASES OF JOINTS AND SOFT TISSUES | |
| EA201400484A1 (en) | TRANSDERMAL MEANS FOR THE TREATMENT AND PREVENTION OF DISEASES OF JOINT AND SOFT TISSUES | |
| RU2019102890A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING FLURBIPROPHEN | |
| EA200500942A1 (en) | MEANS FOR TREATING JOINT DISEASES | |
| NZ606177A (en) | Compositions for the treatment of actinic keratosis | |
| JP6100510B2 (en) | Anti-cold medicine | |
| RU2014148062A (en) | INJECTION PHARMACEUTICAL COMPOSITION OF DEXKETOPROFEN AND TRAMADOL | |
| RU2771952C1 (en) | Treatment for inoperable oral squamous cell carcinoma in cats | |
| JP7156825B2 (en) | External pharmaceutical composition | |
| RU2013126798A (en) | COMBINED THERAPY BY DEXAMETASONE | |
| JP7229678B2 (en) | External pharmaceutical composition | |
| EA202000248A1 (en) | ANTI-SARS-CoV-2 VIRAL ANTIPROVIR |